Telomerase Immortalization of Principal Cells from Human Collecting Duct. + save

Date Added
June 30th, 2014
PRO Number
Pro00017363
Researcher
Phillip Bell
Keywords
Kidney
Summary

Patients with autosomal dominant polycystic kidney disease (ADPKD) have cysts in their kidneys. These balloon-like structures are lined with cells and we are very interested in understanding the derangement in the function of these cells that lead to cyst formation. In order to accomplish this, we need to isolate the cells that line the cyst structures and put them in a cell culture media. We will then use a procedure so that the cells will continue to grow in culture, indefinitely. We can then study the function of these cells to get more information on ADPKD.

Institution
MUSC
Recruitment Contact
Stacy Steele
843-876-2368
steeles@musc.edu

The Impact of Human Papilloma Virus Vaccination in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients + save

Date Added
June 3rd, 2014
PRO Number
Pro00025387
Researcher
Katherine Twombley
Keywords
Kidney, Pediatrics, Transplant, Vaccine
Summary

The aim of the study is to determine the impact of the human papilloma virus (HPV) vaccination in Pediatric Chronic Kidney Disease, Dialysis, and Transplant Patients

Institution
MUSC
Recruitment Contact
Harvey Frampton
843-792-9454
frampton@musc.edu

Pilot study to assess relative merits of Hexabrix versus Visipaque for risk of acute kidney injury post cardiac catheterization and intervention. + save

Date Added
May 27th, 2014
PRO Number
Pro00020077
Researcher
Richard Katzberg
Keywords
Cardiovascular, Kidney
Summary

Patients over 18 years of age who are scheduled for a cardiac catheterization procedure at the Medical University of South Carolina will have the opportunity to participate in a study to see if signs of Acute Kidney Injury could be detected earlier (through urine biomarkers) than it would be normally (through changes in kidney blood tests). Participants will be randomized to one of two iodinated contrasts (Hexabrix or Visipaque) and will be asked to undergo a CT scan of the kidneys 24 hours after the cardiac catheterization procedure.

Institution
MUSC
Recruitment Contact
Aleksander Krazinski
(843)876-7148
krazinsk@musc.edu

A Phase II Randomized, Double-Blind Study of Dalantercept plus Axitinib Compared to Placebo plus Axitinib in Patients with Advanced Renal Cell Carcinoma + save

Date Added
May 13th, 2014
PRO Number
Pro00033034
Researcher
Harry Drabkin
Keywords
Cancer, Cancer/Genitourinary, Drug Studies, Kidney, Men's Health, Women's Health
Summary

This study is for individuals with renal cell carcinoma (RCC). The purpose of this study is:

•To find out whether the study treatment can stop your RCC from growing, or prevent it from growing as fast as it would without dalantercept.
•To evaluate the safety of the study treatment in subjects with RCC.
•To find out if the study treatment has an effect on biomarkers (molecules that indicate how well you respond to study treatment) in your blood and/or tissue.

Participants will receive a dose of dalantercept or placebo (a substance with inactive drug that looks the same as dalantercept) plus axitinib. It is expected that a participant will be on this study for a variation of time (total duration will vary per subject).

Institution
MUSC
Recruitment Contact
Seth Price
843-792-1918
pricesr@musc.edu

Role of Sphingolipids in the Development of Diabetic Nephropathy + save

Date Added
February 25th, 2014
PRO Number
Pro00032064
Researcher
Maria Lopes-virella
Keywords
Diabetes, Kidney
Summary

The purpose of this study is to investigate sphingolipids, a very biologically active class of lipids transported in lipoproteins, in patients with diabetes who have kidney disease (nephropathy). Lipoproteins are particles in blood which transport not only cholesterol and fats but also sphingolipids. Lipoproteins also play an important role in the development of diabetes complications, including nephropathy. This study will investigate the role of the sphingolipids in VLDL (Very Low Density Lipoprotein), LDL (Low Density Lipoprotein) and HDL (High Density Lipoprotein) in the development of nephropathy in diabetes.

Institution
MUSC
Recruitment Contact
Andrea Semler
843-789-6802
semleraj@musc.edu

An Open-Label, Multicenter, Randomized Phase 2 Study Evaluating the safety and efficacy of Docetaxel in combination with Ramucirumab (IMC-1121B) drug product or IMC-18F1 or without investigational therapy as second-line therapy in patients with locally advanced or metastatic transitional cell carcinoma of the bladder, urethra, ureter or renal pelvis following disease progression on first-line platinum based therapy + save

Date Added
January 14th, 2014
PRO Number
Pro00011809
Researcher
Thomas Keane
Keywords
Bladder, Cancer, Cancer/Genitourinary, Drug Studies, Kidney, Men's Health, Women's Health
Summary

This study will compare how bladder cancer responds to treatment with one of three regimens docetaxel, docetaxel with ramucirumab DP or docetaxel with IMC-18F1. The response to treatment will be measured by the length of time on assigned arm before the disease progresses. The study will also look at how long the tumor stays the same size, or in the event of a decrease in tumor size, how long the decrease in tumor size continues. The study will also look at the side effects of the chemotherapy arm compared with the side effects of chemotheapy combined with either investigational agent. The study will also gather information on the levels of ramucirumab DP or IMC-18F1 in the blood.

Institution
MUSC
Recruitment Contact
Jessica Jenkins
843-876-0630
jenkijn@musc.edu

Identification and characterization of “permeability factor” in blood of patients with proteinuric kidney diseases + save

Date Added
December 18th, 2013
PRO Number
Pro00018380
Researcher
Milos Budisavljevic
Keywords
Kidney
Summary

Overwhelming evidence exists that some types of proteinuric kidney diseases are causerd by factor(s) present in patients' blood. Identification and characterization of such factor(s) would greatly help in beter and noninvasive diagnosis of such conditions, development of better therapeutic options and potentially reveal underlying pathogenic mechanisms.
Owing to tremendous capabilities of proteomics facility within the Division of Nephrology we developed experiments that we think will result in significant improvement in our knoledge of major kidney diseases.

Institution
MUSC
Recruitment Contact
Milos Budisavljevic
(843) 792-4123
budisamn@musc.edu

A Randomized, Multicountry, Multicenter, Double-Blind, Parallel, Placebo-Controlled Study of the Effects of Atrasentan on Renal Outcomes in Subjects with Type 2 Diabetes and Nephropathy SONAR: Study of Diabetic Nephropathy with Atrasentan + save

Date Added
November 26th, 2013
PRO Number
Pro00029894
Researcher
Ruth Campbell
Keywords
Diabetes, Kidney
Summary

If you are an adult with type 2 diabetes mellitus and chronic kidney disease (diabetic nephropathy), you may be eligible to take part in a clinical research study called SONAR.
The purpose of this study is to find out if an investigational drug called atrasentan slows the progression of chronic kidney disease. Qualified participants will be randomly assigned to take either atrasentan by mouth or placebo (inactive pill). Study medication, study visits, blood work and study procedures will be provided free of charge.

Institution
MUSC
Recruitment Contact
Vickie Hunt
843-792-7852
huntv@musc.edu

The Use of the Newest Vital Sign and Short Health Literacy Survey in Identifying Health Literacy and Its Correlation to Nutritional Parameters among ESRD patients on Hemodialysis in Charleston, South Carolina + save

Date Added
November 16th, 2013
PRO Number
Pro00027798
Researcher
Rachel Sturdivant
Keywords
Kidney
Summary

End stage renal disease patients on dialysis will be screened and asked to participate in a health literacy survey during regular dialysis treatment days. Two health literacy survey tools will be used: The Newest Vital Sign which is a six-question nutritional label format health literacy tool and the Short Health Literacy Survey, a 3 question health literacy tool.
Nutritional and anthropometric parameters normally collected as part of the hemodialysis treatment will be obtained

Institution
MUSC
Recruitment Contact
Aileen Grace Cielo
843-792-4123
cielo@musc.edu

A Randomized, Placebo-Controlled, Parallel-Group, Double-Blind Study of H.P. Acthar Gel (Acthar) in Treatment-Resistant Subjects with Persistent Proteinuria and Nephrotic Syndrome due to Idiopathic Membranous Nephropathy (iMN) + save

Date Added
October 8th, 2013
PRO Number
Pro00013639
Researcher
Milos Budisavljevic
Keywords
Kidney, Rare Diseases
Summary

This study is designed to see if the drug Acthar can help persons with proteinuria and nephrotic syndrome that is due to Idiopathic Membranous Nephropathy (iMN). Qualified participants will be randomly assigned to one of two treatment groups and will receive either injections of study drug or placebo (no drug in it). Participants will be taught how to safely give the injections to themselves at home and will learn how the dose is adjusted during the treatment period. The treatment period lasts 24 weeks and is followed by a 24 week observation period.

Institution
MUSC
Recruitment Contact
Caroline Counts
843 792 8980
counts@musc.edu